Primary extranodal lymphoma of the glands. Literature review and options for best practice in 2019

Basit Öğe Kaydı
dc.contributor.authorBelkacemi, Yazid
dc.contributor.authorSio, Terence T.
dc.contributor.authorColson-Durand, Laurianne
dc.contributor.authorOnal, Cem
dc.contributor.authorVilla, Salvador
dc.contributor.authorAnacak, Yavuz
dc.contributor.authorKrengli, Marco
dc.contributor.authorThariat, Juliette
dc.contributor.authorUgurluer, Gamze
dc.contributor.authorMiller, Robert C.
dc.contributor.authorMirimanoff, Rene-Olivier
dc.contributor.authorOzsahin, Mahmut
dc.contributor.authorNhu Hanh To
dc.date.accessioned2019-10-27T09:45:53Z
dc.date.available2019-10-27T09:45:53Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstractPrimary extranodal non-Hodgkin's lymphomas (EN-NHL) are a heterogeneous group of malignancies that involve numerous entities with significant difference in terms of tumor site locations, prognostic factors, biology expression, and therapeutic options. In the literature, many EN-NHL types were reported from limited series which only allowed narrow views for elucidating prognostic factors and defining the role of loco-regional therapies in the era of new systemic and biologically targeted therapies. The Rare Cancer Network (RCN), an international multidisciplinary consortium, has published a number of reports on several EN-NHL sites which included many gland locations. In this review, we will focus on the recent literature for a selected number of EN-NHL types in both exocrine and endocrine gland locations. We aim to provide renewed and clear messages for the best practice in 2019 for diagnosis, histopathology, treatments, and also their prognostic implications. We believe that better understanding of molecular and genetic characteristics of these particular diseases is crucial for an appropriate management in the era of personalized treatment developments.en_US
dc.identifier.doi10.1016/j.critrevonc.2019.01.005en_US
dc.identifier.endpage19en_US
dc.identifier.issn1040-8428
dc.identifier.issn1879-0461
dc.identifier.pmid30819450en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage8en_US
dc.identifier.urihttps://doi.org/10.1016/j.critrevonc.2019.01.005
dc.identifier.urihttps://hdl.handle.net/11454/29204
dc.identifier.volume135en_US
dc.identifier.wosWOS:000461262800002en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofCritical Reviews in Oncology Hematologyen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLymphomaen_US
dc.subjectExtranodal non-Hodgkinlymphomaen_US
dc.subjectGlandsen_US
dc.subjectRadiation therapyen_US
dc.subjectClinical practiceen_US
dc.subjectRare canceren_US
dc.subjectRituximaben_US
dc.titlePrimary extranodal lymphoma of the glands. Literature review and options for best practice in 2019en_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu